Sight Sciences (SGHT) Revenue & Revenue Breakdown
Sight Sciences Revenue Highlights
Latest Revenue (Y)
$79.87M
Latest Revenue (Q)
$20.16M
Main Segment (Y)
Surgical Glaucoma
Sight Sciences Revenue by Period
Sight Sciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $79.87M | -1.47% |
| 2023-12-31 | $81.06M | 13.63% |
| 2022-12-31 | $71.33M | 45.70% |
| 2021-12-31 | $48.96M | 77.12% |
| 2020-12-31 | $27.64M | 18.38% |
| 2019-12-31 | $23.35M | 210.07% |
| 2018-12-31 | $7.53M | - |
Sight Sciences generated $79.87M in revenue during NA 2024, up -1.47% compared to the previous quarter, and up 342.07% compared to the same period a year ago.
Sight Sciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $20.16M | -5.68% |
| 2024-06-30 | $21.37M | 10.93% |
| 2024-03-31 | $19.27M | 2.74% |
| 2023-12-31 | $18.75M | -6.29% |
| 2023-09-30 | $20.01M | -14.75% |
| 2023-06-30 | $23.47M | 24.69% |
| 2023-03-31 | $18.82M | -8.37% |
| 2022-12-31 | $20.54M | 9.99% |
| 2022-09-30 | $18.68M | 8.40% |
| 2022-06-30 | $17.23M | 15.78% |
| 2022-03-31 | $14.88M | 1.33% |
| 2021-12-31 | $14.69M | 12.09% |
| 2021-09-30 | $13.10M | 4.52% |
| 2021-06-30 | $12.54M | 45.17% |
| 2021-03-31 | $8.63M | -3.96% |
| 2020-12-31 | $8.99M | 3.93% |
| 2020-09-30 | $8.65M | 147.03% |
| 2020-06-30 | $3.50M | -46.09% |
| 2020-03-31 | $6.50M | - |
Sight Sciences generated $20.16M in revenue during Q3 2024, up -5.68% compared to the previous quarter, and up 85.88% compared to the same period a year ago.
Sight Sciences Revenue Breakdown
Sight Sciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| Dry Eye | $3.96M | $6.75M | $5.74M | $2.46M |
| Surgical Glaucoma | $75.90M | $74.31M | $65.59M | $46.50M |
Latest
Sight Sciences's latest annual revenue breakdown by segment (product or service), as of Dec 24: Surgical Glaucoma (95.04%), and Dry Eye (4.96%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dry Eye | $305.00K | $1.52M | $1.13M | $1.01M | $2.54M | $1.58M | $1.14M | $1.49M | $1.79M | $1.60M | $1.33M | $1.01M | $762.00K | $655.00K | $547.00K |
| Surgical Glaucoma | $18.77M | $18.63M | $20.24M | $18.26M | $17.15M | $18.43M | $21.40M | $17.33M | $18.75M | $17.07M | $15.90M | $13.87M | $13.92M | $12.45M | $11.99M |
Latest
Sight Sciences's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Surgical Glaucoma (98.40%), and Dry Eye (1.60%).
Sight Sciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CNMD | CONMED | $1.31B | $316.70M |
| VREX | Varex Imaging | $811.00M | $199.80M |
| AVNS | Avanos Medical | $687.80M | $170.40M |
| AORT | Artivion | $388.54M | $95.78M |
| TCMD | Tactile Systems | $292.98M | $73.09M |
| FNA | Paragon 28 | $256.18M | $61.02M |
| KIDS | OrthoPediatrics | $204.73M | $52.80M |
| SIBN | SI-BONE | $167.18M | $40.34M |
| ANIK | Anika Therapeutics | $166.66M | $38.75M |
| LUNG | Pulmonx | $83.79M | $20.39M |
| NPCE | NeuroPace | $79.91M | $21.06M |
| SGHT | Sight Sciences | $79.87M | $20.16M |
| CVRX | CVRx | $51.29M | $13.37M |
| RPID | Rapid Micro Biosystems | $28.05M | $7.60M |
| OFIX | Orthofix Medical | - | $198.62M |